Oraya Therapeutics (Newark, CA) an early-stage medical device company focused on radiation treatment of age related macular degeneration, closed a $42M Series C financing. Participants include Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.

Applied Genetic Technlogies (Alachua, Fl) a clinical-stage biopharmaceutical company developing gene therapy treatments for Alpha-1 Antitrypsin Deficiency and Leber’s Congenital Amaurosis, closed a $11.8M Series C financing. Participants include InterWest, Intersouth Partners and MedImmune Ventures.

Visiogen (Irvine, CA) a commercial-stage medical device company focused on products for cataract and refractive patients, closed a $40M Series D financing. Participants include Novartis Venture Fund, Technology Partners, Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures and Foundation Medical Partners.

iScience Interventional (Menlo Park, CA) a commercial-stage microcatheter device for the treatment of ocular diseases open-angle glaucoma and clinical-stage development focused on wet-AMD, closed a $20.5M Series F financing. Participants include Affinity Capital Management, Johnson & Johnson Development Corp., L Capital Partners, Clarian Health Ventures, Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management [...]

Novagali Pharma (France) drug development laboratory focused on ophthalmology, closed a $21.9M series D financing. Participants include Edmond de Rothschild Investment Partners, Siparex Ventures, CDC Enterprise Innovation, Auriga Ventures, Multinova and CPR Private Equity.

ESBATech (Switzerland) clinical-stage biotechnology company focused on antibody fragments, closed a $22M Series B financing. Participants include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners

Neuron Systems (Burlington, MA) development-stage company focused on the treatment of retinal diseases, closed a $8.9M Series A financing. Participants include Domain Associates and Johnson & Johnson Development Corp.

Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.

ArGentis Pharmaceuticals (Memphis, TN) development-stage biopharmaceutical company focused the development of autoimmunity and ophthalmology therapeutics, closed a $2.0M Series financing. Participants include Innova Memphis.

Alimera Sciences (Alphertta, GA) focused upon delivery of therapeutics agents for degenerative eye ailments such as diabetic macular edema, age related macular degeneration and glaucoma, closed a $30M Series C financing. Participants include BA Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners and Venrock Associates

Kolis Scientific (Morrisville, NC) is developing an outpatient-based treatment for a common ophthalmic condition, has closed a $15.1M Series A financing led by Quaker BioVentures, De Novo Ventures and Spray Venture Partners.